Lung Cancer

OBJECTIVES: Immune checkpoint inhibitors (ICIs) have provided a breakthrough in the treatment of non-small cell lung cancer (NSCLC) patients, but only some patients benefit substantively. Identifying definitive predictive biomarkers could overcome this limitation.MATERIALS AND METHODS: We selected 146 metastatic NSCLC patients treated with anti-PD-(L)1. Immunohistochemistry of HLA-I, PD-L1 and CD73 was performed in 122 tumor biopsies at diagnosis. The association with patients, tumor parameters, and the predictive value to ICI treatment were determined.RESULTS: In our cohort, 42%, 25%, and 21% of the tumors exhibited high levels of HLA-I, PD-L1, and CD73, respectively. Lung adenocarcinomas displayed elevated CD73 levels, compared with lung squamous cell carcinomas (P=0.026). High PD-L1 was significantly correlated with high levels of HLA-I (P=0.005) and of CD73 (P=0.025). Patients with high-level HLA-I tumors exhibited more favorable clinical outcomes following ICI, with a median overall survival of 30.7months (95% confidence interval [CI]: 18.3months-not reached), compared with 18.2months (95% CI: 12.4-25.2months) in patients with low-level HLA-I tumors (P=0.016). The median progression-free survival (PFS) for patients with high-level HLA-I tumors was 18.5months (95% CI: 11.1-57.1months), longer than patients with low-level HLA-I tumors, whose median PFS was 9.2months (95% CI: 7.2-11.9months) (P=0.006). In a multivariable analysis, high-level HLA-I was independently associated with lower risk of progression to ICI (HR=0.46, 95% CI 0.24-0.87; P=0.018).CONCLUSIONS: High-level HLA-I were associated with better clinical outcomes to ICI in our cohort of NSCLC patients. Therefore, further investigations are warranted to refine this biomarker and validate its efficacy in prospective and larger set of patients.